Evidence map›Paper›PMID 37474248›Full record

ArticleThe Journal of infectious diseases2023

Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody.

Dafna Abelson, Jennifer Barajas, Lauren Stuart, Do Kim, Arumugapradeep Marimuthu, Chris Hu, Brent Yamamoto, Eric Ailor, Kevin J Whaley, Hong Vu and 12 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 1 country.

Dafna AbelsonMapp Biopharmaceutical, Inc, San Diego, California, USA.
Jennifer BarajasMapp Biopharmaceutical, Inc, San Diego, California, USA.
Lauren StuartMapp Biopharmaceutical, Inc, San Diego, California, USA.
Do KimMapp Biopharmaceutical, Inc, San Diego, California, USA.
Arumugapradeep MarimuthuMapp Biopharmaceutical, Inc, San Diego, California, USA.
Chris HuMapp Biopharmaceutical, Inc, San Diego, California, USA.
Brent YamamotoMapp Biopharmaceutical, Inc, San Diego, California, USA.
Eric AilorMapp Biopharmaceutical, Inc, San Diego, California, USA.
Kevin J WhaleyMapp Biopharmaceutical, Inc, San Diego, California, USA.
Hong VuIntegrated Biotherapeutics, Rockville, Maryland, USA.
Krystle N AgansGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Viktoriya BorisevichGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Daniel J DeerGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Natalie S DobiasGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Courtney WoolseyGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Abhishek N PrasadGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Jennifer E PeelGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
William S LawrenceGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Robert W CrossGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Thomas W GeisbertGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Karla A FentonGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Larry ZeitlinMapp Biopharmaceutical, Inc, San Diego, California, USA.
The University of Texas Medical Branch at Galveston · USMapp Biopharmaceutical (United States) · USIntegrated BioTherapeutics (United States) · US

Funding

Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for FilovirusesU19AI142785 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GEISBERT, THOMAS WILLIAM · 2019 to 2023
$35.5M
NIAID NIH HHS U19 AI142785
6 · The paper itself

Abstract

Marburg virus (MARV) causes a hemorrhagic fever disease in human and nonhuman primates with high levels of morbidity and mortality. Concerns about weaponization of aerosolized MARV have spurred the development of nonhuman primate (NHP) models of aerosol exposure. To address the potential threat of aerosol exposure, a monoclonal antibody that binds MARV glycoprotein was tested, MR186YTE, for its efficacy as a prophylactic. MR186YTE was administered intramuscularly to NHPs at 15 or 5 mg/kg 1 month prior to MARV aerosol challenge. Seventy-five percent (3/4) of the 15 mg/kg dose group and 50% (2/4) of the 5 mg/kg dose group survived. Serum analyses showed that the NHP dosed with 15 mg/kg that succumbed to infection developed an antidrug antibody response and therefore had no detectable MR186YTE at the time of challenge. These results suggest that intramuscular dosing of mAbs may be a clinically useful prophylaxis for MARV aerosol exposure.

Indexed as

MarburgvirusMarburg Virus DiseaseAerosolsAnimalsAntibodies, MonoclonalHumansPrimatesAerosolsAntibodies, MonoclonalaerosolantibodyMarburg virusmonoclonal

Identifiers

PMID37474248
PMCPMC11009508
OpenAlexW4384924277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.